John Cumbers

1 month ago | nature.com | Erika DeBenedictis |Edwin Kite |Robin D. Wordsworth |Nina Lanza |Ramses M. Ramirez |John Cumbers | +1 more

AbstractTerraforming Mars has long captured the imagination but has received surprisingly little rigorous study. Progress in Mars science, climate science, launch capabilities and bioscience motivates a fresh look at Mars terraforming research. Since Sagan’s time, it has been understood that terraforming Mars would involve warming to enable oxygenic photosynthesis by engineered microbes, followed by slow oxygen build-up enabling more complex life.

2 months ago | synbiobeta.com | John Cumbers

In this episode, John Cumbers speaks with Harshal Chokhawala, co-founder and CEO of ZymoChem, about how the company is reengineering the foundations of materials science using microbial fermentation. Harshal discusses his scientific journey from organic chemistry to building a carbon-conserving biotech platform capable of producing bio-based adipic acid, a key component in nylon 66. Their recent partnership with Lululemon aims to bring sustainable, high-performance textiles to market.

Apr 16, 2024 | synbiobeta.com | John Cumbers

On this SynBioBeta podcast, John Cumbers talks with Edward Shenderovich, the Founder and CEO of Synonym, a company creating bioeconomy infrastructure to help next-generation bioproducts scale and get to market. Edward will speak at this year’s SynBioBeta conference on “Scaling Biological Capacity,” and in today’s episode, John and Edward will discuss how Synonym addresses some of the challenges in biomanufacturing with its technology-driven products and focus.

Feb 13, 2024 | synbiobeta.com | John Cumbers

On this SynBioBeta podcast, John Cumbers talks with Eben Bayer, the CEO of Ecovative, a pioneering company at the forefront of developing sustainable materials using mycelium. John and Eben will discuss Ecovative’s journey toward creating a billion pounds of mycelium, explore some of the cutting-edge agricultural technology used in mushroom growing, and discuss the transformative potential of new mycelium crops in consumer goods.

Dec 5, 2023 | synbiobeta.com | John Cumbers

On this SynBioBeta podcast, John Cumbers talks with Sean McClain, founder, and CEO of Absci, a generative AI drug creation company on a mission to create better drugs for patients faster. Sean and John will continue some of the discussion that we started on the SynBioBeta stage around generative AI and its critical role in drug discovery, some news from AbSci’s recent R&D day, and Sean’s recent visit to Congress to discuss the opportunities and threats from AI and bio.